ALS | Jotup

Solaris Provides Disclosure Clarifications

Retrieved on:

Wednesday, March 13, 2024

VANCOUVER, British Columbia, March 13, 2024 (GLOBE NEWSWIRE) -- Solaris Resources Inc. (TSX: SLS; OTCQB: SLSSF) (“Solaris” or the “Company”) is issuing the following news release as a result of a continuous disclosure review by the British Columbia Securities Commission.

Key Points:

VANCOUVER, British Columbia, March 13, 2024 (GLOBE NEWSWIRE) -- Solaris Resources Inc. (TSX: SLS; OTCQB: SLSSF) (“Solaris” or the “Company”) is issuing the following news release as a result of a continuous disclosure review by the British Columbia Securities Commission.
The Company will file an amended technical report as soon as practicable with disclosure relating to the indicative starter pit removed from such disclosure.
The Company has also made certain disclosure in its corporate presentation regarding potential economic results for the property and consensus analyst estimates for the MRE.
The Company is retracting the foregoing disclosure noted in this paragraph and confirms it has not completed an economic assessment at the project.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. (AMLX)

Retrieved on:

Wednesday, March 13, 2024

ALS, Patient, GPM, Defendant, News, Suite, Investment, GAAP, Court, Pharmaceutical industry

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points:

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
On November 9, 2023, Amylyx released its third quarter 2023 financial results, missing GAAP earnings per share consensus estimates by approximately 29%.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
Glancy Prongay & Murray LLP, Los Angeles

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc. (AMLX) Shareholders

Retrieved on:

Wednesday, March 13, 2024

Apoptosis, ALS, Telephone, Patient, LLP, CLASS, NEXT, COST, Court, Cryptocurrency

NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Amylyx Pharmaceuticals, Inc. ("Amylyx" or the "Company") (NASDAQ: AMLX) of a class action securities lawsuit.

Key Points:

NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Amylyx Pharmaceuticals, Inc. ("Amylyx" or the "Company") (NASDAQ: AMLX) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Amylyx investors who were adversely affected by alleged securities fraud between November 11, 2022 and November 8, 2023.
Follow the link below to get more information and be contacted by a member of our team:
AMLX investors may also contact Joseph E. Levi, Esq.
For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights

Retrieved on:

Wednesday, March 13, 2024

ACT, Disease, Natural history, Survival, ALS, CNM, Risk, Patient, Biomarker, EAP, Mortality, NDA, Data, FDA, AFL, Pharmaceutical industry

In December 2023, Clene reported new data from the ongoing open-label extension of the HEALEY ALS Platform Trial.

Key Points:

In December 2023, Clene reported new data from the ongoing open-label extension of the HEALEY ALS Platform Trial.
Clene plans to submit additional data to the FDA to advance the CNM-Au8 accelerated approval discussions in 2024.
In December 2023, Clene announced the publication of a peer-reviewed article describing brain target engagement by CNM-Au8.
Clene expects that its resources as of December 31, 2023, will be sufficient to fund its operations into the fourth quarter of 2024.

Amylyx Pharmaceuticals, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; April 9, 2024 deadline

Retrieved on:

Wednesday, March 13, 2024

Patient, Defendant, Apoptosis, ALS, Pharmaceutical industry

LOS ANGELES, March 12, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Amylyx Pharmaceuticals, Inc. investors that a lawsuit was filed on behalf of investors that purchased Amylyx securities between November 11, 2022 and November 8, 2023, inclusive (the “Class Period”).

Key Points:

LOS ANGELES, March 12, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Amylyx Pharmaceuticals, Inc. investors that a lawsuit was filed on behalf of investors that purchased Amylyx securities between November 11, 2022 and November 8, 2023, inclusive (the “Class Period”).
Investors are encouraged to contact attorney Lesley F. Portnoy , by phone 310-692-8883 or email : [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com .
The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing.

NFL Running Back Nyheim Hines Supports Nation's Largest St. Patrick’s Day Fundraising Campaign to Benefit Muscular Dystrophy Association

Retrieved on:

Wednesday, March 13, 2024

Cleveland Browns, Nyheim Hines, ALS, MDA, Partnership, Muscular dystrophy, Research, Muscular Dystrophy Association, Family, NFL, Neuromuscular disease

Hines proudly wears the 2024 limited edition MDA Shamrocks t-shirt designed by MDA Board member Matthew Plummer who lives with neuromuscular disease.

Key Points:

Hines proudly wears the 2024 limited edition MDA Shamrocks t-shirt designed by MDA Board member Matthew Plummer who lives with neuromuscular disease.
With family members who live or have lived with muscular dystrophy, Hines continues to generate awareness and raise critical funds for the neuromuscular disease community.
"It's truly humbling to continue to raise awareness for the neuromuscular disease community through the mission of Muscular Dystrophy Association.
It’s our privilege to collaborate with Nyheim to bring the fruits of our mission to his family and millions more across the country."

Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer

Retrieved on:

Wednesday, March 13, 2024

AAV, ALS, Assistant, Central nervous system, University, Florida College, SOD1, CNS, Running, Traffic barrier, IND, Biogen, DSM-IV codes, Therapy, CMO, Medical director, University of Florida, Pharmaceutical industry

LEXINGTON, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Toby Ferguson, M.D., Ph.D., as Chief Medical Officer (CMO), effective March 25, 2024.

Key Points:

LEXINGTON, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Toby Ferguson, M.D., Ph.D., as Chief Medical Officer (CMO), effective March 25, 2024.
During his tenure, he built and developed teams focused on neuromuscular and movement disorders, overseeing strategy for these areas across Biogen R&D.
Prior to joining Biogen, Ferguson was Assistant Professor of Neurology, Shriners Pediatric Research Center and Temple University School of Medicine.
Voyager represents for me an extraordinary opportunity to fulfill this mission.”

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GrafTech, Instacart, Cassava, and Amylyx and Encourages Investors to Contact the Firm

Retrieved on:

Wednesday, March 13, 2024

The Company sells and delivers a range of products in the food, alcohol, consumer health, pet care, and ready-made meals categories, in addition to others.

Key Points:

The Company sells and delivers a range of products in the food, alcohol, consumer health, pet care, and ready-made meals categories, in addition to others.
The Company offers its services through a mobile application and website, while also providing software-as-a-service solutions to retailers.
In addition, the complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
For more information on the Amylyx class action go to: https://bespc.com/cases/AMLX

Cerevance Announces Presentation at Alzheimer’s Research UK Conference

Retrieved on:

Wednesday, March 13, 2024

Brain, Conference, ALS, Central nervous system, CNS, Microglia, NLRP3, KCNK13, Frontotemporal dementia, Poster, Therapy, Neuroinflammation, FTD

BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced plans to present a poster at the upcoming Alzheimer’s Research UK Conference, taking place in Liverpool, United Kingdom, March 20-21, 2024.

Key Points:

BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced plans to present a poster at the upcoming Alzheimer’s Research UK Conference, taking place in Liverpool, United Kingdom, March 20-21, 2024.
Overview: Cerevance’s NETSseq platform enables the identification of novel targets, such as KCNK13 (THIK1), from specific cell types in the human brain.
Following the discovery of KCNK13, Cerevance has developed CVN293, a novel compound that selectively inhibits KCNK13 and reduces the release of IL-1β from microglia dependent on NLRP3.
CVN293 shows promise in potentially addressing CNS conditions characterized by neuroinflammation, such as frontotemporal dementia (FTD), Amyotrophic lateral sclerosis (ALS), and Alzheimer’s disease.

AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease

Retrieved on:

Wednesday, March 13, 2024

Neurology, Serum, EAE, Multiple sclerosis, ALS, Disease, Patient, Biomarker, Masitinib, Research, Mouse, Science, University, MD, Euronext, Alzheimer's disease, Cytokine, AN, BioRxiv, FDA, NFL, Nerve, FIRST, AFL, NDD, Guideline, Pharmaceutical industry

Findings have been published on the bioRxiv preprint service as an article entitled, ‘Masitinib limits neuronal damage, as measured by serum neurofilament light chain concentration, in a model of neuroimmune-driven neurodegenerative disease’.

Key Points:

Findings have been published on the bioRxiv preprint service as an article entitled, ‘Masitinib limits neuronal damage, as measured by serum neurofilament light chain concentration, in a model of neuroimmune-driven neurodegenerative disease’.
The neuroprotective action of masitinib was studied in an animal model of experimental autoimmune encephalitis (EAE).
Results showed that masitinib can significantly lower serum NfL levels, and by extension therefore, neuronal damage, in a neuroimmune-driven neurodegenerative disease model, with concomitant reduction in pro-inflammatory cytokines and slowing of clinical symptoms.
Masitinib limits neuronal damage, as measured by serum neurofilament light chain concentration, in a model of neuroimmune-driven neurodegenerative disease.